Answers are grounded in this paper and cite their sources.
Purpose: Anti-citrullinated protein antibodies (ACPA) positivity decreases in elderly-onset rheumatoid arthritis (EORA), likely due to immunosenescence and clinical heterogeneity. This study aimed to evaluate the multi-biomarker disease activity (MBDA) score as an alternative diagnostic marker for rheumatoid arthritis (RA) in patients with new-onset joint symptoms, focusing on ACPA–negative cases stratified into young-onset RA (YORA) and EORA. Patients and Methods: This retrospective study was conducted at two institutions in Hokkaido, Japan (2018– 2022). Patients with new-onset joint symptoms who had not received prior RA therapy were included. Baseline serum samples were analyzed for MBDA and high-sensitivity C-reactive protein (hsCRP). Diagnostic performance for RA was evaluated using sensitivity, specificity, accuracy, area under the curve, and logistic regression. Results: Among 257 patients, 90 were < 60 years (RA, n = 42) and 167 were ≥ 60 years (RA, n = 84). In YORA, ACPA was the strongest predictor (odds ratio [OR]: 170.48, P < 0.01). In ACPA-negative YORA, both MBDA (OR: 6.51, P = 0.03) and hsCRP (OR: 15.56, P = 0.02) were significant, and their combination improved accuracy to 86.9% (OR: 18.00, P < 0.01). In EORA, ACPA showed lower accuracy (70.1%), whereas MBDA was higher (74.9%). In ACPA-negative EORA, the combination of MBDA and hsCRP provided the highest predictive ability (accuracy: 72.8%; OR: 43.52, P < 0.01). Conclusion: MBDA, particularly when combined with hsCRP, provides clinically meaningful diagnostic value for RA in patients with new-onset joint symptoms, particularly in ACPA-negative YORA and EORA. Trial Registration: This study was retrospectively registered in the University Hospital Medical Information Network (UMIN000057829).
No takes yet. Share an insight, caveat, or question.
Hiura et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: